BIOCUREX INC 
By
BioCurex, Inc. ("BioCurex" or "the Company") is a biotechnology company
developing products for cancer diagnosis, imaging, and therapy that target a
global oncology market forecast to reach over
The RECAF(TM) marker has been found on every cancer tissue that BioCurex has studied to date, including on many common, severe cancers: breast, lung, gastric, prostate, and leukemia. This characteristic indicates that RECAF(TM) is capable of detecting more than one type of cancer, which is a limitation of many currently available cancer markers. The Company's RECAF(TM) technology is reported to have high levels of clinical sensitivity and specificity (measures of cancer marker accuracy), successfully detecting over 90% of cancer in blood and tissue samples. A serum-based assay using RECAF(TM) recently identified twice as many prostate cancers as the current standard for prostate cancer detection, the prostate-specific antigen (PSA) test.
In early 2006, a RECAF(TM)-based test also detected 90% to 93% of Stage I and Stage II (early stage) breast cancer samples, without any false positives. This data supports BioCurex's aim of reducing human suffering through the early detection of cancer or cancer recurrence after treatment. Moreover, due to its ability to differentiate between cancerous and normal cells, RECAF(TM) technology may facilitate the administration of targeted therapeutics that attack cancer cells but do not damage healthy tissue.
About Crystal Research Associates, LLC
Crystal Research Associates, LLC is an independent research firm that
provides institutional-quality, fee-based research to small and mid-cap
companies. Crystal Research Associates' unique and novel product, the
Executive Informational Overview(R) (EIO(R)), is free of investment ratings,
target prices, and forward-looking financial models. The EIO(R) presents a
crystal clear, detailed report on a company (public or private) in a manner
that is easily understood by the Wall Street financial community. The EIO(R)
details a company's product/technology/service offerings, market size(s), key
intellectual property, leadership, growth strategy, competition, risks,
audited financial statements, key events, and other such fundamental
information. Crystal Research Associates has offices in
Forward-Looking Safe Harbor Statement
Statements in this news release regarding future financial and operating results, potential applications of the Company's technology, opportunities for the Company, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements including, limited operating history, need for future capital, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Company's periodic reports, including forms filed with SEC.
These statements, and other forward-looking statements, are not guarantees of future performance and involve risks and uncertainties. Crystal Research Associates assumes no obligation to update any of the forward-looking statements in this release.
SOURCE Crystal Research Associates, LLC
